FedEx Life Sciences targets GLP-1-driven healthcare logistics growth

FedEx Life Sciences has been launched as the parcel group’s dedicated push into healthcare logistics, a business FedEx says generates $10 billion a year and accounts for more than 10% of annual revenue. The move ties the company more closely to fast-growing shipments of GLP-1 drugs and other temperature-sensitive medicines, where failed delivery can carry high product and compliance costs.

The new unit, announced earlier in July, brings together FedEx’s healthcare sales, engineering and quality functions for pharmaceutical customers, Chief Customer Officer Brie Carere told CNBC. FedEx is seeking to build on prior investments in cold-chain transport, controlled storage, rapid delivery and shipment monitoring across routes linking manufacturers, warehouses, laboratories, pharmacies and patients.

What is FedEx Life Sciences?

FedEx Life Sciences is a dedicated organization inside FedEx focused on healthcare and pharmaceutical shipping rather than a separate delivery network. The company is adding specialist oversight to its existing global air, ground, customs and parcel systems so that patient-critical shipments receive priority handling among the roughly 18 million packages FedEx moves each day, according to Carere.

Healthcare is one of four business-to-business verticals FedEx has prioritized, alongside automotive, aerospace and data centers. Management has said these areas can support faster growth, better margins and demand that is less tied to consumer spending cycles.

Carere told CNBC that healthcare shipping represents an $80 billion market opportunity growing at a 7% compound annual rate over the next six years. She said some categories are expanding more quickly, with GLP-1 medicines growing at about 20% and cell and gene therapies at about 25%.

GLP-1 drugs include Eli Lilly’s Mounjaro, used for diabetes, and Zepbound, used for obesity, according to CNBC. Biologics, another key category for cold-chain transport, are medicines made from living organisms and include vaccines and gene therapies.

Why cold-chain shipping commands a premium

Many specialty medicines must remain within tight temperature ranges through each stage of transport. Carere said customers pay more for security, compliance and temperature control, while also seeking to cut losses from spoiled products and avoid regulatory problems.

Lora Cecere, founder of Supply Chain Insights, told CNBC that advances in science and the growth of biologics and personalized medicine have made healthcare supply chains more complex. She said the sector offers stronger profit and margin opportunities because pharmaceutical companies can absorb premium logistics costs, especially when the value of a shipment is high.

FedEx is expanding cold-storage capacity at hubs tied to major pharmaceutical trade lanes. In Memphis, Tennessee, the company already operates a healthcare warehouse with five temperature zones, including freezer storage at minus 150 degrees Celsius, CNBC reported.

The company also points to technology as part of its pitch. Carere said about 40% of FedEx healthcare customers use FedEx Surround, a real-time monitoring platform that applies machine learning to anticipate disruptions. FedEx also offers SenseAware for shipments requiring more advanced tracking, added security and quality assurance.

Deutsche Bank analyst Richa Harnain told CNBC that healthcare customers value those tools. She also said FedEx and United Parcel Service are not necessarily competing directly for the same business in every area. UPS said last month it would spend $48 million expanding its temperature-controlled healthcare network across Europe, Asia and the Americas, and reported $11.2 billion in healthcare revenue for 2025.

Cardinal Health is another participant in medical logistics and distribution. FedEx told CNBC that Cardinal is both a customer and a strategic collaborator, following a 2013 partnership that gave joint customers access to warehouses and distribution centers across the United States.

The healthcare push comes as FedEx reshapes its revenue mix. FedEx Express accounted for about 86% of total revenue in the fiscal fourth quarter ended May 31, while FedEx Freight contributed nearly 10% before being spun off as a separate public company on June 1. FedEx has said it expects revenue of $98 billion by 2029 through premium B2B and B2C volumes, compared with current annual revenue of about $86 billion after the freight separation.

This story draws on original reporting from CNBC.